News & Events

Events

WCBP

Jan 23-25
Washington, DC

OTx Xchange

Feb 28
Manchester Grand Hyatt San Diego, CA

AACR

April 5-10
San Diego, CA

BEBPA HCP

May 14-16
College Park, MD

ADLM

July 30-Aug 1
Chicago, IL

BPS

Aug 19-22
Boston, MA

OTS

Oct 6-9
Montreal, Quebec, Canada

SfN

Oct 5-9
Chicago, IL

MEDICA

Nov 11-14
Messe Dusseldorf Dusseldorf, Germany

News

FEBRUARY 25, 2025

Innovative Research to Advance Oligonucleotide Therapeutics now published in the Journal of Nucleic Acid Therapeutics

Our recently published manuscript reviews the current landscape and key hurdles faced in ONTs and offers antibody-based assays as an othogonal approach for localization and quantification of ONTs throughout drug development.

FEBRUARY 3, 2025

Rockland Launches AccuSignal™ E. coli ELISA Kit for Precise Detection of HCPs in Biologic Manufacturing

The AccuSignal E. coli ELISA Kit is designed to detect E. coli Host Cell Proteins (HCPs), including from strains such as B and K-12, to ensure bioprocess consistency and safety of therapeutic products.

OCTOBER 25, 2024

Abzyme Therapeutics' pH-Dependent Anti-CD3 Antibody Secures Key Patent

Abzyme Therapeutics LLC, a Rockland-affiliated biotechnology company, has reached a significant milestone in its pursuit to develop innovative antibody-based therapies.

AUGUST 22, 2024

The Jackson Laboratory Expands Partnership with Rockland and antibodies-online to Exclusively Offer Highly Characterized FcRn Antibodies for the Assessment of Therapeutic Drugs

The Jackson Laboratory Expands Partnership with Rockland and antibodies-online to Exclusively Offer Highly Characterized FcRn Antibodies for the Assessment of Therapeutic Drugs.

APRIL 16, 2024

Rockland, antibodies-online, and The Jackson Laboratory Partner to Exclusively Offer Innovative Genome Editing Tools to Researchers Worldwide

The Jackson Laboratory partners with Rockland and antibodies-online to provide genomic tools for global immuno-oncology research, diagnostics, and therapeutics development.

JANUARY 11, 2024

Rockland Launches Impurity Detection Kit for Accurate Measurement of Nuclease Across a Spectrum of Therapeutic Manufacturing Methods

The AccuSignal Nuclease ELISA Kit is designed to detect endonuclease to evaluate manufacturing processes for biological therapeutics, gene therapy vectors, vaccine preparations, and more.

OCTOBER 17, 2023

Rockland Launches Novel Analytical Tools to Assess Drug Delivery Revolutionizing Oligonucleotide Therapeutic Development

The first and only panel of specialty reagents designed to detect PS modifications independent of sequence, format, or location, streamlining candidate triage for unparalleled cost and time savings in early-stage non-clinical and pre-clinical discovery assessment of...

FEBRUARY 1, 2023

Rockland Launches Early Access Program for ModDetect™ Anti-PS Panel

Rockland, a pioneer in life science solutions, is excited to announce the initiation of the Early Access Program for its ModDetect Anti-PS Monoclonal Antibody Panel.

NOVEMBER 10, 2022

Rockland Immunochemicals, Inc. and Cytiva Life Sciences to launch PrismA ELISA Kit

In partnership with Cytiva Life Sciences, Rockland is announcing the newest addition to the portfolio - the PrismA ELISA kit. This new kit is designed to reduce the complexity in process-related impurity analytical assay development.

FEBRUARY 22, 2022

Rockland Immunochemicals, Inc. collaborates with Jefferson Institute for Bioprocessing to offer complete bioprocessing solutions

Rockland Immunochemicals, Inc. (Rockland) and the Jefferson Institute for Bioprocessing (JIB) announced today that an agreement has been signed under which both entities are able to utilize one another's strengths to provide complete and scalable bioprocessing solutio...

FEBRUARY 10, 2022

Rockland Immunochemicals, Inc. announces acquisition of antibodies-online GmbH and investment from BroadOak Capital Partners

With its acquisition of antibodies-online GmbH, Rockland expands its capabilities, product portfolio, and geographic footprint to serve scientists engaged in the discovery, development, and delivery of complex therapies and critical diagnostics ...

OCTOBER 18, 2021

Rockland expands infectious disease portfolio with new partner, Diagnostic BioSystems

Diagnostic BioSystems (DBS), a provider of cutting-edge in vitro diagnostics and high quality Immunohistochemistry (IHC) reagents has signed a distribution agreement with Rockland Immunochemicals, Inc ...

SEPTEMBER 28, 2021

From Philadelphia to Saudi Arabia: A partnership in support of biotech expansion

Rockland President and Chief Executive Officer, James Fendrick and the King Abdullah International Medical Research Center (ك KAIMRC) recently signed a Memorandum ...

SEPTEMBER 9, 2020

Unique Scientific-Academic Partnership Advances Revolutionary CRISPR in a Box™ Educational Gene Editing Kit

Introducing CRISPR in a Box - it is not a new crunchy cereal or the latest snack - it is an educational tool kit consisting of state-of-the-science gene editing technology that could be coming to a school near you ...

AUGUST 12, 2020

Rockland Employees Working on COVID-19 Antibody Development Featured in Recent Article by Montgomery County Community College

Rockland greatly values our local partnerships-one in particular is our partnership with Montgomery County Community College (MCCC) and their Biotechnology Associate Professor and Program Coordinator, Dr. Margaret Bryans ...

MAY 29, 2020

Rockland Develops Antibody Proven to Detect SARS-CoV-2 in Patient Samples

Rockland Immunochemicals Inc. has developed a critical antibody reagent essential to antibody tests used to determine SARS-CoV-2 exposure for patients suspected to have contracted COVID-19 ...